Collegium Pharmaceutical, Inc. Common Stock
COLL Real Time Price USDRecent trades of COLL by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in COLL holdings by institutional investors
Quarterly net insider trading by COLL's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$10,000 Jul 20, 2026 Issue: Health Issues
-
$30,000 Jul 17, 2026 Issue: Health Issues
-
$20,000 Apr 21, 2026 Issue: Health Issues
-
$60,000 Apr 20, 2026 Issue: None
-
$10,000 Apr 17, 2026 Issue: Health Issues
-
$10,000 Jan 16, 2026 Issue: Health Issues
-
$10,000 Oct 20, 2025 Issue: Health Issues
-
$10,000 Sep 25, 2025 Issue: Health Issues
-
$10,000 Jul 14, 2025 Issue: Health Issues
-
$10,000 Apr 15, 2025 Issue: Health Issues
-
$10,000 Oct 17, 2024 Issue: Health Issues
-
$10,000 Jul 15, 2024 Issue: Health Issues
-
$10,000 Oct 20, 2023 Issue: Health Issues
-
$10,000 Jul 20, 2023 Issue: Health Issues
-
$60,000 Jan 19, 2022 Issue: Health Issues
-
$60,000 Oct 20, 2021 Issue: Health Issues
-
$60,000 Jul 20, 2021 Issue: Health Issues
-
$10,000 Apr 20, 2017 Issue: Health Issues
-
$20,000 Jan 23, 2017 Issue: Health Issues
-
$30,000 Oct 14, 2016 Issue: Health Issues
-
$40,000 Jul 19, 2016 Issue: Health Issues
-
$10,000 Apr 20, 2016 Issue: Health Issues
Former government officials who have lobbied for COLL
9 former government officials from 6 congressional offices at 3 lobbying firms have lobbied for COLL, most recently Jul 20, 2026.
-
Keith Studdard House Legislative Director, Rep. Marsha Blackburn -
John Herzog Senate Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President -
John Ray House Legislative Assistant, Rep. Mike Kelly -
Laura Kemper Senate Counsel, Sen. John Cornyn; Deputy Assistant Secretary for Legislation, U.S. Department of Health and Human Services; Counselor to the Secretary, U.S. Department of Health and Human Services -
Brett Meeks Senate Deputy Health Policy Director, Senate Committee on Health, Education, Labor and Pensions; Deputy Press Secretary, Office of Senator Lamar Alexander
-
Kristin Fritsch House Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Senior Legislative Assistant, Office of Congresswoman Cathy McMorris Rodgers; Professional Staff Member House Committee on Energy and Commerce -
Kelsey Carlson Congress Special Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of Commerce
-
Jessie Brairton House Senior Legislative Asst/Legislative Asst, Rep. Lamar Smith; LC/Asst, Senate Special Aging Committee
COLL Estimated quarterly lobbying spending
COLL Revenue by Segment or Geography
New COLL patent grants
-
Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 02, 2020
-
Patent Title: Process of making stable abuse-deterrent oral formulations May. 12, 2020
-
Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Jan. 07, 2020
-
Patent Title: Abuse-deterrent drug formulations Jan. 07, 2020
-
Patent Title: Process of making stable abuse-deterrent oral formulations Jan. 29, 2019
-
Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 26, 2018
-
Patent Title: Process of making stable abuse-deterrent oral formulations May. 15, 2018
-
Patent Title: Abuse-deterrent drug formulations Sep. 19, 2017
-
Patent Title: Process of making stable abuse-deterrent oral formulations Aug. 22, 2017
-
Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Jun. 20, 2017
-
Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Mar. 14, 2017
-
Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Feb. 02, 2016
-
Patent Title: Abuse-deterrent pharmaceutical compositions of opiods and other drugs Jun. 02, 2015
-
Patent Title: Tamper-resistant pharmaceutical compositions of opioids and other drugs Sep. 23, 2014
-
Patent Title: Abuse-deterrent drug formulations Jun. 24, 2014
-
Patent Title: Abuse-deterrent pharmaceutical compositions of opioids and other drugs Oct. 15, 2013
-
Patent Title: Pharmaceutical compositions for sleep disorders Aug. 20, 2013
-
Patent Title: Abuse-deterrent drug formulations May. 28, 2013
-
Patent Title: Modified release compositions of milnacipran Sep. 20, 2011
-
Patent Title: Abuse-deterrent drug formulations Aug. 10, 2010
-
Patent Title: Modified release compositions of milnacipran Apr. 27, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to COLL from public contracts
Recent insights relating to COLL
Recent picks made for COLL stock on CNBC
ETFs with the largest estimated holdings in COLL
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $COLL stock a Buy, Sell, or Hold?
- What is the price target for $COLL stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $COLL stock?
- Who owns the most shares of $COLL stock?
- What funds own $COLL stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view COLL Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- Address Stoughton, MA
- Market Cap 741.6 million
- Employees 423
- Industrial Classification Pharmaceutical Preparations
Collegium Pharmaceutical, Inc. Common Stock (COLL) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Collegium Pharmaceutical, Inc. Common Stock (COLL).
Quiver Premium charts COLL's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at COLL, per a recent SEC DEF 14A filing. We estimate that the median employee at COLLEGIUM PHARMACEUTICAL, INC is paid $223,542.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|